55 results
424B5
NKTX
Nkarta Inc
25 Mar 24
Prospectus supplement for primary offering
8:15pm
of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have business operations;
our dependence
8-K
EX-99.1
NKTX
Nkarta Inc
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
to the impact on our business of the COVID-19 pandemic or similar public health crises.
These and other risks and uncertainties are described more fully
8-K
EX-99.1
6tzbqxup 3sy0jd
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am
8-K
EX-99.1
ic5 z0p1hp
5 Jul 23
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
4:09pm
8-K
EX-99.1
xkksfo6z jbvsjhpe
11 May 23
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
4:06pm
S-3/A
h9opju68
24 Apr 23
Shelf registration (amended)
5:21pm
8-K
EX-99.1
2ljkeob6
30 Mar 23
Nkarta Announces Departure of Chief Financial & Business Officer
4:11pm
8-K
EX-99.1
uvpsyy5ah4lmt
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
8-K
EX-99.1
hlrdwygeyrm1iw
11 Aug 22
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.1
pk2sscvhtth7ar01
16 May 22
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
4:09pm
8-K
EX-99.1
v266wz7dp5om4r
12 May 22
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
4:09pm
424B5
nkww59 z6
26 Apr 22
Prospectus supplement for primary offering
4:02pm